Alterations of serum trace elements in patients with type 2 diabetes

Zhang, Hongmei; Yan, Chen‐Hua; Yang, Zhen; Zhang, Weiwei; Niu, Yixin; Li, Xiaoyong; Qin, Li; Su, Qing

doi:10.1016/j.jtemb.2016.12.017

Cited by 71 publications

(59 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the present study and from clinical trials overall differ from the general findings from observational studies, the majority of which have demonstrated positive, direct associations between Se and the development of T2D 5 7–9. Further, within the Selenium Trial, we have previously reported the results of a cross-sectional investigation of baseline Se and prevalent T2D that revealed statistically significantly increased odds of T2D among those who had the highest concentrations of blood Se levels, with an OR (95% CI) of 1.77 (1.16 to 2.71) for those in the highest tertile of Se versus the lowest 23.…”

Section: Discussioncontrasting

confidence: 99%

“…Later clinical trials, specifically the Selenium and Vitamin E Cancer Prevention Trial (SELECT) and the Selenium Trial, showed no statistically significant overall increased risk for T2D risk after supplementation with 200 µg/day Se as compared with placebo 2 3. In contrast, results from observational studies have generally demonstrated an increased risk for T2D among those with higher blood or toenail Se concentrations 5–9. However, these results are challenging to interpret because of marked geographical variation in dietary intake of Se, which in turn elicits major differences in circulating concentrations of Se.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Selenium supplementation and insulin resistance in a randomized, clinical trial

Jacobs

Lance

Mandarino

et al. 2019

BMJ Open Diab Res Care

View full text Add to dashboard Cite

ObjectiveWhile controversial, observational and randomized clinical trial data implicate the micronutrient selenium (Se) in the development of type 2 diabetes (T2D). The aim of this study was to test the hypothesis that Se supplementation adversely affects pancreatic β-cell function and insulin sensitivity.Research design and methodsIn a subset of 400 individuals participating in a randomized, placebo-controlled trial of Se at 200 µg/day for colorectal adenomatous polyps, fasting plasma glucose and insulin were measured before randomization and within 6 months of completing intervention. Change in the homeostasis model assessment-β cell function (HOMA2-%β) and insulin sensitivity (HOMA2-%S) were compared between arms. A subgroup of 175 (79 Se and 96 placebo) participants underwent a modified oral glucose tolerance test (mOGTT) at the end of intervention and change in glucose values was assessed.ResultsNo statistically significant differences were observed for changes in HOMA2-%β or HOMA2-%S between those who received Se compared with placebo. After a mean of 2.9 years on study, mean HOMA2-%β values were 3.1±24.0 and 3.1±29.8 for the Se and placebo groups, respectively (p=0.99). For HOMA2-%S, the values were −0.5±223.2 and 80.9±1530.9 for the Se and placebo groups, respectively (p=1.00). Stratification by sex or age did not reveal any statistically significant effects on insulin sensitivity by treatment group. For mOGTT, mean baseline fasting blood glucose concentrations were significantly higher among participants in the placebo group compared with the Se group (96.6±14.6 and 92.3±12.0, respectively; p=0.04), a trend which remained through the 20 min assessment.ConclusionsThese findings do not support a significant adverse effect of daily Se supplementation with 200 µg/day of selenized yeast on β-cell function or insulin sensitivity as an explanation for previously reported associations between Se and T2D. Further clarification of longer term effects of Se is needed.Clinical trial registryNIH Clinical Trials.gov numberNCT00078897.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Selenium supplementation and insulin resistance in a randomized, clinical trial

Jacobs

Lance

Mandarino

et al. 2019

BMJ Open Diab Res Care

View full text Add to dashboard Cite

show abstract

“…dietary Zn, protein intake, blood Zn concentration, other factors determining the hair growth, environmental factors, etc. Both positive and negative correlations between blood serum/plasma Zn levels have been reported in healthy and diabetic subjects [ 44 , 45 ].…”

Section: Discussionmentioning

confidence: 99%

The Relationship between Dietary, Serum and Hair Levels of Minerals (Fe, Zn, Cu) and Glucose Metabolism Indices in Obese Type 2 Diabetic Patients

Król

Bogdański

Suliburska

et al. 2018

Biol Trace Elem Res

View full text Add to dashboard Cite

The aim of this study was to assess the levels of Zn, Fe and Cu in the serum and hair, and dietary intake of type 2 diabetic patients and their association with glucose and lipid indices. The study was conducted on 62 people aged 40-78 years (31 diabetic patients and 31 healthy subjects, who were the control group). The content of trace elements in the hair and serum was analysed with the AAS method. The serum insulin, HbA1c, glucose, total cholesterol and triacylglycerol concentrations were measured by means of RIA, HPLC and colorimetric methods, respectively. The diabetic patients were found to have significantly higher dietary iron intake, higher hair Fe and lower serum Zn concentrations than the non-diabetic subjects, while the hair Zn and Cu contents were comparable in both groups. The serum Zn and Cu levels of the diabetic subjects were negatively correlated with the serum glucose, the serum Zn and Cu/Zn ratio was inversely correlated with the serum total cholesterol and the serum insulin level was positively associated with the hair Cu/Zn ratio. The results of this study indicate that the trace element status (Zn, Fe, Cu), as reflected in the blood serum and hair, may be disturbed due to metabolic derangement occurring in diabetes.

show abstract

“…50,51 It has been reported that selenium concentration was higher in diabetic patients than in healthy people. 52,53 Once developing DM, the body needs more antioxidant species to fight against oxidative and inflammatory responses. Therefore, selenium as a potent antioxidant and a physiological modulator is inspired for use in DM care.…”

Section: Se-based Nanomedicines For Oncotherapymentioning

confidence: 99%

Selenium as a pleiotropic agent for medical discovery and drug delivery

Guan¹,

Yan²,

Li³

et al. 2018

IJN

View full text Add to dashboard Cite

Selenium as a biologically active element lends much support to health maintenance and disease prevention. It is now presenting pleiotropic effects on therapy and drug delivery. In this study, a profiling on the physiological functions, therapeutic significances, clinical/preclinical performances, and biomedical and drug delivery applications of selenium in different modalities was carried out. Major interests focused on selenium-based nanomedicines in confronting various diseases pertaining to selenium or not, especially in antitumor and antidiabetes. Furthermore, the article exclusively discusses selenium nanoparticles featured by ameliorative functions with emphasis on their applications in medical practice and drug delivery. The state-of-the-art in medical discovery as well as research and development on selenium and nano-selenium is discussed in this review.

show abstract

Alterations of serum trace elements in patients with type 2 diabetes

Cited by 71 publications

References 42 publications

Selenium supplementation and insulin resistance in a randomized, clinical trial

Selenium supplementation and insulin resistance in a randomized, clinical trial

The Relationship between Dietary, Serum and Hair Levels of Minerals (Fe, Zn, Cu) and Glucose Metabolism Indices in Obese Type 2 Diabetic Patients

Selenium as a pleiotropic agent for medical discovery and drug delivery

Contact Info

Product

Resources

About